TrialInvestigational new drugs2016

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.

Giorgio Scagliotti et al.PubMed ↗Publisher ↗

No numbers read from the abstract.